MERCK & CO. INC. reported its experimental drug sacituzumab tirumotecan met primary endpoints in a late-stage trial involving 776 uterine cancer patients. The treatment outperformed standard chemotherapy by extending survival and delaying disease progression in advanced cases. Positive Phase 3 data strengthens Merck's oncology pipeline as it seeks to diversify revenue beyond its existing blockbuster treatments.

Trial Data Shows Improved Survival Rates